Published in Cardiovascular Week, August 11th, 2008
"This study investigates the effects of recombinant human erythropoietin analog darbepoetin-alpha on quality of life and emotional stress, evaluated by relevant questionnaires in patients with CHIF and anemia. Forty-one CHF patients [New York Heart Association class: II-III; left ventricular (LV) ejection fraction (EF) < 40%; hemoglobin < 12.5 g/dl; serum creatinine < 2.5 mg/dl] were randomized (1 : 1) to receive either 3-month darbepoietin-alpha...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.